Nidanilimab
Modify Date: 2024-09-21 10:41:23
Nidanilimab structure
|
Common Name | Nidanilimab | ||
|---|---|---|---|---|
| CAS Number | 2171061-85-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of NidanilimabNidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2]. |
| Name | Nidanilimab |
|---|
| Description | Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2]. |
|---|---|
| Related Catalog | |
| Target |
IL-1α IL-1β |
| In Vitro | Nidanilimab (CAN04; 20 µg/mL; 小鼠 MC38 结肠癌细胞) 具有糖工程介导增强的抗体依赖性细胞毒性 (ADCC, EC50<1 nM)[2]。 Nidanilimab (20 µg/mL; 小鼠 MC38 结肠癌细胞) 阻断 IL1α 和 IL1β 信号通路，IC50 值分别为 3.9 nM和 4.1 nM[2]。 |
| In Vivo | Nidanilimab (CAN04; 10 mg/kg; i.p.; 裸 C57Bl/6 小鼠) 增加了两种常用的铂基化疗药物顺铂 (HY-17394)/吉西他滨 (HY-17026) 和卡铂 (HY-17393)/吉西他滨 (HY-17026) 的疗效[1]。 Animal Model: Nude C57Bl/6 mice with LU2503 NSCLC PDX model[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection Result: Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy. |
| References |
| No Any Chemical & Physical Properties |